SUPPLEMENTAL INFORMATION FOR ANNABIDIOL, INC. (ACBD)

July 18, 2023

AnnaBidiol, Inc. ("The Company") has entered into a Merger Agreement with Digital Research Solutions, Inc. ("Digital RS").

Digital Research Solutions, Inc. ("Digital RS") was incorporated in 2015. Digital RS will operate as a wholly owned subsidiary of the Company. Digital RS is an innovative programming, AI software technology development, and advisory Company.

The Merger will be effective upon delivery of the financial statements from Digital RS, which are expected on or about August 15, 2023. Digital RS has agreed to purchase 500,000 Series A preferred shares from the prior control party. Additionally, Digital RS has agreed to purchase 33,520,000 common shares of AnnaBidiol, Inc. from the previous control party in a private transaction.

On July 17, 2023, The Company appointed Kelly Kirchhoff as a director. Kelly Kirchhoff has also been appointed the CEO of AnnaBidiol, Inc, and David D Peralta has resigned as CEO.

By virtue of the Merger and without any further action on the part of Digital RS, AnnaBidiol, Inc., or the Acquisition Sub, each of the Digital Research Solutions Inc., Shares will be converted into 33,520,00 shares of validly issued, fully paid, and non-assessable common stock of AnnaBidiol. Digital RS will be issued a total of 33,520,00 common shares of AnnaBidiol, Inc., as a result of the Merger, constituting roughly 83.82% of the then issued and outstanding common stock of 39,990,306, and such shares shall be distributed pro rata to the holders of the Digital RS. All shares of AnnaBidiol Common Stock issued upon the exchange of Digital RS shares in accordance with the terms hereof shall (i) contain a restricted securities legend in compliance with the Securities Act and (ii) be deemed to have been issued in full satisfaction of all rights pertaining to such Digital RS shares.

I attest that the foregoing is true and correct.

Kelly Kirchhoff

CEO